According to a recent study on artificial intelligence (AI) by JAMA Cardiology, model applications show promise for improving the accuracy and speed of event classification in multicenter clinical trials. The study examined the potential for natural language processing (NLP) models to accurately classify heart failure (HF) hospitalizations compared with clinical adjudication. According to Forbes, the biggest risk with AI in clinical trials is the potential for accidental exposure of patient data and data generation bias. As a result, patient data will be compromised, and profiles could face rejection. In the case of event adjudication, it is reasonable to evaluate AI-generated output against the traditional adjudication approach,” said the authors of the study, titled The Future of Clinical Trials: Artificial to Augmented to Applied Intelligence.

Source: Forbes November 15, 2023 19:17 UTC